Obesity Ages Your Heart Decades Faster Than Your Birth Certificate Shows

With 880 million adults globally classified as obese and an aging population projected to double by 2050, the convergence of these two epidemics is driving cardiovascular disease to unprecedented levels. This state-of-the-art review in the European Heart Journal, authored by Ruperez, Madeo, de Cabo, Kroemer, and Abdellatif, provides a thorough comparative analysis of how obesity and biological aging intersect at molecular, cellular, tissue, and whole-organ levels within the cardiovascular system.

At the whole-organ level, both obesity and aging independently produce strikingly similar cardiovascular phenotypes: left ventricular diastolic dysfunction, left atrial remodeling, myocardial hypertrophy, increased fibrosis, arterial stiffening, impaired vasodilatory function, and elevated peripheral vascular resistance. Importantly, these changes occur even in 'metabolically healthy' obese individuals and in laboratory mice maintained under optimal conditions without diabetes, hypertension, or dyslipidemia — underscoring that obesity and aging exert direct, intrinsic cardiovascular effects beyond their associated comorbidities.

At the molecular and cellular level, the review identifies a compelling set of shared hallmarks between obese and aged cardiovascular cells: impaired autophagy and proteostasis, mitochondrial dysfunction, excessive reactive oxygen species accumulation, DNA damage and genomic instability, telomere shortening, epigenetic dysregulation, and premature accumulation of senescent cells. Obesity-driven lipotoxicity, chronic low-grade inflammation (termed 'inflammaging' in the aging context), and insulin resistance further amplify these mechanisms. Multi-cohort human studies confirm that BMI positively correlates with omics-based biological age measures linked to major cardiovascular and cerebrovascular events, and mid-life obesity has been associated with up to 10 years of life lost.

The review then pivots to therapeutic implications, examining how metabolic interventions targeting obesity may simultaneously antagonize key aging pathways. GLP-1 receptor agonists (e.g., semaglutide) and SGLT2 inhibitors demonstrate cardiovascular benefits that extend beyond glucose and weight control, partly through restoration of autophagy, reduction of oxidative stress, and attenuation of senescence. Caloric restriction — the gold standard for lifespan extension across model organisms — and its mimetics such as spermidine and rapamycin activate autophagy and suppress mTOR signaling, mechanisms directly relevant to both obesity and aging. The authors argue these interventions may benefit non-obese elderly individuals at cardiovascular risk by targeting shared aging biology.

The review acknowledges important caveats: much mechanistic evidence derives from animal models, causality between obesity-induced molecular changes and accelerated aging remains incompletely established in humans, and the concept of 'metabolically healthy obesity' may obscure subclinical cardiovascular damage. The authors call for longitudinal studies integrating multi-omics biological aging clocks with cardiovascular endpoints in obese and aging cohorts to better disentangle these relationships and guide therapeutic development.